A family office with USA offices has a focus on the social impact as an overall investment mandate. The firm aims to fund cutting-edge therapeutics companies, through their accelerator arm while also investing in later-stage assets. The firm will invest globally. For their accelerator arm, the firm is seeking companies with pre-clinical and clinical therapeutics with a minimum initial investment of $1M-$10M, with the possibility of follow-on investments. The firm generally invests in companies with lead assets in Phase I – III clinical trials, and the amount of the allocation is based on the raise and pre-money valuation of the company.
The firm is looking for therapeutics companies, with a particular interest in biologics assets such as antibody-based technologies, cell and gene therapies. The firm mandate focused on regenerative and personalized medicine in oncology, neurodegenerative, orphan, and rare disease applications.
The firm will only consider companies that have more than two assets in the pipeline and experienced management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply